Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 1,053 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 1,053 shares of Insmed stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $183,401.01. Following the sale, the insider directly owned 57,037 shares in the company, valued at $9,934,134.29. This trade represents a 1.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $241,968.68.
• On Monday, November 3rd, Michael Alexander Smith sold 27,130 shares of Insmed stock. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40.

Insmed Price Performance

Insmed stock opened at $170.27 on Friday. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The firm’s fifty day moving average is $190.31 and its 200 day moving average is $151.37. The company has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same period in the previous year, the business earned ($1.27) earnings per share. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. Sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as “worth keeping an eye on,” which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
• Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
• Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed

Wall Street Analyst Weigh In

A number of analysts have weighed in on INSM shares. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Guggenheim reduced their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Cantor Fitzgerald boosted their price objective on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Rothschild & Co Redburn started coverage on shares of Insmed in a research note on Thursday, December 4th. They set a “buy” rating and a $263.00 price target for the company. Finally, Morgan Stanley set a $157.00 price objective on Insmed in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.64.

Institutional Trading of Insmed

Several large investors have recently bought and sold shares of INSM. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. ORG Partners LLC increased its position in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank purchased a new position in Insmed in the 2nd quarter worth $28,000. Stone House Investment Management LLC acquired a new stake in Insmed during the 3rd quarter worth about $29,000. Finally, SBI Securities Co. Ltd. lifted its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 166 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.